NPRA Banner

               
Product Search   QUEST3+ System   Enquiries   Sitemap  

Escapelle® & Postinor-2® (levonorgestrel): Levonorgestrel-containing emergency hormonal contraception ─ New advice for users of hepatic-enzyme inducers

User Rating: 3 / 5

Star ActiveStar ActiveStar ActiveStar InactiveStar Inactive
 

Date: 15 March 2017

 

Description:

The metabolism of levonorgestrel is known to be increased by concomitant use of liver enzyme inducers, mainly inducers of CYP3A4 enzymes. This resulting reduction in plasma levonorgestrel levels may reduce contraceptive efficacy of levonorgestrel-containing emergency hormonal contraceptives. Women seeking emergency contraception who have used an enzyme-inducing medicine within the last 4 weeks are advised to use a non-hormonal emergency contraceptive, i.e. a copper intrauterine device (Cu-IUD). If this is not an option, they should be advised to double the usual dose of levonorgestrel from 1.5 mg to 3 mg to compensate for the reduction in plasma levonorgestrel levels. The information on the medicine’s outer carton and package insert is being revised to include the new dosing instructions for this category of women. For further details on this updated advice, please refer to the Direct Healthcare Professional Communication (DHPC) issued by Pahang Pharmacy Sdn. Bhd. in agreement with NPRA.

 

 

 

National Pharmaceutical Regulatory Agency (NPRA)

Lot 36, Jalan Universiti (Jalan Prof Diraja Ungku Aziz), 46200 Petaling Jaya, Selangor, Malaysia.

  • Phone: +603-7883 5400

 

 

DISCLAIMER

The Government of Malaysia and the National Pharmaceutical Regulatory Agency are not responsible for any loss or damage caused by the usage of any information obtained from this website.

Site Last Modified

  • Last Modified: Friday 13 December 2024, 16:27:32.

Search

Main Menu English